Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring

被引:4
|
作者
Zhou, Yangkun [1 ]
Yue, Yang [1 ]
Fan, Siyu [1 ]
Jia, Qiaojun [1 ]
Ding, Xianfeng [1 ]
机构
[1] Zhejiang Sci Tech Univ, Sch Life Sci & Med, Hangzhou 310018, Peoples R China
关键词
Triple-negative breast cancer (TNBC); Long non-coding RNA (lncRNA); Biomarker; Therapeutic target; LONG NONCODING RNA; PROMOTES PROLIFERATION; CELL-PROLIFERATION; INVASION; METASTASIS; APOPTOSIS; PROTEIN; IDENTIFICATION; SUPPRESSES; RESISTANCE;
D O I
10.1007/s12033-021-00368-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have shown that long non-coding RNAs (lncRNAs) are involved in several gene expression regulation processes, including epigenetic regulation, transcriptional regulation, post-transcriptional regulation, and translation regulation. It also plays a crucial role in the regulation of several characteristics of cancer biology, and the dysregulation of lncRNA expression in cancer may be part of the cause of cancer progression. Meanwhile, more and more studies are trying to determine the association between lncRNA expression and TNBC, as well as the functional role and molecular mechanism of the abnormally expressed lncRNA. Therefore, this review lists some abnormal lncRNAs in TNBC, further analyzes their molecular mechanisms and biological roles in the development of TNBC, and summarizes the potential of lncRNAs as biomarkers and therapeutic targets of TNBC, so as to provide ideas for clinical diagnosis, targeted therapy, and prognosis monitoring of TNBC.
引用
收藏
页码:1093 / 1102
页数:10
相关论文
共 50 条
  • [1] Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring
    Yangkun Zhou
    Yang Yue
    Siyu Fan
    Qiaojun Jia
    Xianfeng Ding
    Molecular Biotechnology, 2021, 63 : 1093 - 1102
  • [2] Advances in the Treatment of Triple-negative Early Breast Cancer
    Basso, Stefano M. M.
    Santeufemia, Davide A.
    Fadda, Giovanni M.
    Tozzoli, Renato
    D'Aurizio, Federica
    Lumachi, Franco
    MEDICINAL CHEMISTRY, 2016, 12 (03) : 268 - 272
  • [3] Recent advances in the treatment of triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Kunkiel, Michal
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (06): : 433 - 443
  • [4] Advances in the systemic treatment of triple-negative breast cancer
    Lebert, J. M.
    Lester, R.
    Powell, E.
    Seal, M.
    McCarthy, J.
    CURRENT ONCOLOGY, 2018, 25 : S142 - S150
  • [5] Nanomaterials for the Diagnosis and Treatment of Triple-Negative Breast Cancer
    Sun, Xuan
    Li, Dandan
    Lv, Yue
    Zhang, Mengnan
    Qiao, Dianhe
    Zhang, Zuyuan
    Ren, Han
    Zhang, Ying
    Yang, Zhimou
    Gao, Jie
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2024, 16 (06)
  • [6] Perspectives on the potential application of microRNAs in the diagnosis and treatment of triple-negative breast cancer
    Yeqin Wu
    Haitao Song
    Huifang Shi
    Gangping Wang
    Oncology and Translational Medicine, 2025, 11 (01) : 5 - 9
  • [7] Commentary to Recent advances in the treatment of triple-negative breast cancer
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (06): : 444 - 444
  • [8] New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
    El Hejjioui, Brahim
    Lamrabet, Salma
    Joutei, Sarah Amrani
    Senhaji, Nadia
    Bouhafa, Touria
    Malhouf, Moulay Abdelilah
    Bennis, Sanae
    Bouguenouch, Laila
    DIAGNOSTICS, 2023, 13 (11)
  • [9] Evaluation of lncRNAs as Potential Biomarkers for Diagnosis of Metastatic Triple-Negative Breast Cancer through Bioinformatics and Machine Learning
    Soleimani, Shiva
    Pouresmaeili, Farkhondeh
    Far, Iman Salahshoori
    IRANIAN JOURNAL OF BIOTECHNOLOGY, 2024, 22 (03)
  • [10] Advances in immunotherapy for triple-negative breast cancer
    Yang Liu
    Yueting Hu
    Jinqi Xue
    Jingying Li
    Jiang Yi
    Jiawen Bu
    Zhenyong Zhang
    Peng Qiu
    Xi Gu
    Molecular Cancer, 22